Table 5. Combinations of antibiotics received by patients with MRSA and MSSA bacteremia at any time during treatment (N = 2741).
| Combination2 | MRSA (N = 53) UK (N = 49) & Vietnam/Nepal (N = 4) | MSSA (N = 221) | ||
| Overall | UK(N = 193) | Vietnam/Nepal (N = 28) | ||
| Beta-lactam + aminoglycoside3 | 4 (8%) | 60 (27%) | 51 (27%) | 9 (32%) |
| Glycopeptide + aminoglycoside3 | 15 (29%) | 32 (15%) | 30 (16%) | 2 (7%) |
| Beta-lactam + rifampin3 | 0 (0%) | 34 (16%) | 33 (17%) | 1 (4%) |
| Glycopeptide + rifampin3 | 20 (38%) | 32 (15%) | 32 (17%) | 0 (0%) |
| Beta-lactam + fucidic acid3 | 1 (2%) | 33 (15%) | 33 (17%) | 0 (0%) |
| Glycopeptide + fucidic acid3 | 3 (6%) | 6 (3%) | 6 (3%) | 0 (0%) |
| Other combinations 4 | 26 (50%) | 99 (45%) | 78 (41%) | 21 (75%) |
Information on whether combination therapy was used was available for 587 of the 593 patients who were treated, of whom 279 (48%) received combination therapy. Of these, 274 had information on susceptibility to methicillin.
72/274 (26%) of patients received more than one type of combination during the same episode.
Information on whether a given combination was used was missing for 2–3 patients for each combination listed.
112 received another 2-drug combination; 13 received 3 or more drugs in combination. Of the 112 who received a 2-drug combination 34 received a glycopeptide + beta-lactam, 12 received a beta-lactam + fluoroquinolone, 12 received a beta-lactam + clindamycin, and 7 received a beta-lactam + macrolide. The remaining 47 received one of 22 different combinations.